Publications

Journal Article
Multicenter Study Randomized Controlled Trial
Ppublish 414 citations
Open access — free full text available
Open access
Electronic publication date
May 28, 2025

View on Pubmed.gov 40162642 | View on doi.org 10.1056/NEJMoa2... | View the free full text Full text

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

Search for publications in this journal N Engl J Med - 392(20):2001-2012

SOUL Study Group

Abstract

BACKGROUND

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.

METHODS

In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome).

RESULTS

Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively.

CONCLUSIONS

Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).

References

No references provided.

Cited by 414 citations (total)

Journal Article Review

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.

Electronic publication date July 29, 2025

Search for publications in this journal EClinicalMedicine

Areesha Moiz [...] Mark J Eisenberg et al.

Journal Article Review

Obesity-Related Kidney Disease: A Growing Threat to Renal Health.

Electronic publication date July 30, 2025

Search for publications in this journal Int J Mol Sci

Juan León-Román [...] María José Soler et al.

Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

Copyright © 2025 Massachusetts Medical Society.